Skip to content

Globus Medical GMED Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston Scientific logo
Boston ScientificBSX
-$30M-700%
Henry Schein logo
Henry ScheinHSIC

Other financials

Income statement

See full
Revenue$759.9M+27.0%
Gross profit$525.8M+30.6%
Operating income$150.4M+55.0%
Net income$124.3M+64.7%
EPS (diluted)$0.90+66.7%

Balance sheet

See full
Cash & equivalents$561.0M+21.6%
Total debt$116.3M+25.0%
Total equity$4.7B+15.8%
Total assets$5.4B+15.5%

Cash flow

See full
Operating cash flow$202.4M+14.1%
CapEx$39.6M+9.7%
Free cash flow$162.7M+15.3%

Valuation

See full
Market cap$10.76B+15.7%
Enterprise value$10.31B+15.6%
P/E18.3×-31.7×
P/S3.5×-0.2×

Profitability

See full
Gross margin67.9%+7.3pp
Operating margin17.2%+7.0pp
Net margin18.9%+11.5pp
FCF margin19.7%-1.1pp

Returns & leverage

See full
Return on equity13.3%+8.7pp
Debt / equity0.0×
Current ratio4.6×+0.1×

Where this comes from

Reported directly by Globus Medical in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Globus Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Globus Medical's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Globus Medical's contingent consideration fair value adjustments?
Globus Medical (GMED) reported contingent consideration fair value adjustments of $6.35M in Q1 2026.
How has Globus Medical's contingent consideration fair value adjustments changed year-over-year?
Globus Medical's contingent consideration fair value adjustments increased by 3703.6% year-over-year, from $167K to $6.35M.
What is the long-term trend for Globus Medical's contingent consideration fair value adjustments?
Over 2 years (2021 to 2023), Globus Medical's contingent consideration fair value adjustments has grown at a 1.8% compound annual growth rate (CAGR), from $16.81M to $17.43M.